ONO 7579

Drug Profile

ONO 7579

Alternative Names: ONO-7579

Latest Information Update: 13 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 May 2017 Ono Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in United Kingdom (PO) (NCT03182257)
  • 31 Mar 2017 Phase-I clinical trials in Solid tumours in Europe (PO) before March 2017
  • 31 Mar 2017 Phase-I clinical trials in Solid tumours in USA (PO) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top